Stifel Nicolaus assumed coverage on shares of Genocea Biosciences (NASDAQ:GNCA) in a research note issued to investors on Monday morning, BenzingaRatingsTable reports. The brokerage issued a buy rating on the biotechnology company’s stock.

Several other research analysts also recently weighed in on GNCA. Zacks Investment Research upgraded HB Fuller from a sell rating to a hold rating in a research note on Wednesday, July 3rd. ValuEngine downgraded Zumiez from a hold rating to a sell rating in a research note on Tuesday, July 2nd. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $5.13.

NASDAQ:GNCA opened at $3.66 on Monday. The business’s 50-day moving average price is $4.60. Genocea Biosciences has a 1-year low of $2.24 and a 1-year high of $11.28. The company has a market capitalization of $94.76 million, a PE ratio of -0.99 and a beta of 2.41. The company has a debt-to-equity ratio of 1.45, a quick ratio of 2.51 and a current ratio of 2.51.

Genocea Biosciences (NASDAQ:GNCA) last posted its quarterly earnings results on Tuesday, April 30th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06). Equities analysts forecast that Genocea Biosciences will post -2.82 earnings per share for the current fiscal year.

In related news, major shareholder Peter W. Sonsini bought 2,857,142 shares of the company’s stock in a transaction on Monday, June 24th. The shares were acquired at an average cost of $3.50 per share, with a total value of $9,999,997.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 2.33% of the company’s stock.

An institutional investor recently raised its position in Genocea Biosciences stock. NEA Management Company LLC boosted its position in shares of Genocea Biosciences Inc (NASDAQ:GNCA) by 39.8% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,948,269 shares of the biotechnology company’s stock after buying an additional 9,948,269 shares during the period. Genocea Biosciences makes up about 1.1% of NEA Management Company LLC’s portfolio, making the stock its 23rd biggest holding. NEA Management Company LLC owned about 31.10% of Genocea Biosciences worth $20,619,000 at the end of the most recent reporting period.

Genocea Biosciences Company Profile

Genocea Biosciences, Inc, a biopharmaceutical company, discovers and develops novel cancer vaccines. The company uses its proprietary discovery platform, ATLAS, to recall a patient's pre-existing CD4+ and CD8+ T cell immune responses to tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses.

Read More: Diluted Earnings Per Share

Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with's FREE daily email newsletter.